Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ARX 788

X
Drug Profile

ARX 788

Alternative Names: Antibody-drug conjugate - Ambrx/Zhejiang Medicine; ARX-788; JNJ-0683; NCB-001

Latest Information Update: 28 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ambrx
  • Developer Ambrx; NovoCodex Biopharmaceuticals
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies; Small molecules
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III HER2 positive breast cancer
  • Suspended Breast cancer; Gastric cancer; Solid tumours

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for phase-I development in Gastric-cancer(Metastatic disease, Second-line therapy or greater) in China (IV)
  • 07 Mar 2024 Ambrx has been acquired by Johnson & Johnson
  • 25 Jan 2024 Ambryx plans a phase II trial for Breast cancer (Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater, Metastatic disease) in the US (IV) (NCT06224673)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top